GlassScriptPhysician profile
Marc S Behar
NPI 1730180365
$5,416.07
in general payments reported to CMS, 2019-2025
36 companies · $680 in 2025
The $680 reported for 2025 was more than what 80% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $515 · 2021: $703 · 2022: $1,079 · 2023: $922 · 2024: $809 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.34 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $883.97 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $550.66 | 2021-2025 | |
| Astellas Pharma US INC | $456.02 | 2020-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $366.51 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $318.62 | 2019-2022 | |
| Agile Therapeutics, INC. | $311.83 | 2021-2024 | Twirla |
| Evofem Biosciences, INC. | $247.01 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $243.32 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $189.13 | 2023-2025 | Myfembree |
| Millicent US INC | $159.40 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Pfizer INC. | $152.68 | 2019-2024 | |
| Hologic Sales and Service, LLC | $144.52 | 2022 | |
| Myovant Sciences INC. | $138.83 | 2021-2022 | |
| Organon LLC | $135.64 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $108.51 | 2023-2025 | Accrufer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $101.19 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $99.93 | 2019-2021 | |
| Lupin INC. | $98.03 | 2019-2020 | |
| Coopersurgical, INC. | $87.13 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $86.72 | 2019-2020 | |
| Ge Healthcare | $75.26 | 2020 | |
| Scynexis, INC. | $52.26 | 2022 | |
| Allergan, INC. | $48.64 | 2019-2020 | |
| Medtronic, INC. | $48.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.24 | 2025 | |
| Merck Sharp & Dohme LLC | $47.64 | 2024 | Gardasil, Gardasil 9 |
| Daiichi Sankyo INC. | $34.56 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.92 | 2025 | Vpriv |
| Glaxosmithkline, LLC. | $26.68 | 2023 | Arexvy, Shingrix |
| Abbott Laboratories | $22.99 | 2021 | |
| Roche Diagnostics Corporation | $22.39 | 2021 | |
| Gilead Sciences, INC. | $19.50 | 2019 | |
| Duchesnay USA Incorporated | $19.03 | 2019 | |
| Mission Pharmacal Company | $12.71 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.50 | 2019 | |
| Channel Medsystems, INC. | $11.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Behar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.